Rifampicin has five hydroxyl groups on the molecule. However, it was confirmed by LS/MS analysis that for Rif-VitE and Rif-PCL, only one site was reacted. An example chromatograph is shown in Fig. S2 . 
S.2. SMILES and calculation of RIF prodrug logP values
• Volume 1282.295
(2) RIF-PCL
• Volume 2651.707
• Volume 755.912 Figure S3 . Particle size distribution for RIF The RIF-PCL (NC1, ) and RIF-VE nanocarriers with RIF core loadings of 0% (NC2, ) to 10% (NC3, ) and 50% (NC4, ) after freeze drying with trehalose and Poloxamer® F68 as cryoprotectants. After rehydration, the powders were resuspended by brief hand shaking and probe tip sonication.
S.3.
Redispersion of RIF prodrug nanocarrier formulations In order to transport and test the efficacy of these nanocarriers against M. tuberculosis, a dried form of the formulation was prepared. Previously, Kumar et al. used a combination of trehalose and Pluronic F68 as a cryoprotectant during freeze drying to prevent irreversible nanocarrier aggregation [3] . In this work, the same cryoprotectants also protected the nanocarriers against extensive aggregation during freezing and lyophilization.
After rehydrating and resuspending the nanocarriers at a concentration of 1 mg mL -1 RIF with a moderate period of sonication, all formulations redispersed to less than 500 µm ( Fig. S3 ), which was suitable for dosing and in vitro analysis.
The RIF-PCL particles redisperse to 190 nm. The effectiveness of resuspension can be captured in the ratio of the redispersed size, S f , to the initial size, S i , where values close to 1 correspond to good resuspension and values much larger than 1 indicate extensive aggregation. For RIF-PCL, S f /S i = 1.1, which indicates complete protection from aggregation, within experimental error. In contrast, the RIF-VE particles aggregate, with S f /S i = 2.8; however, the final average particle size is 170 nm, which is suitable for injection. There is a smaller population which is present, which corresponds to the primary particle size, prior to lyophilizaiton. Since the intensity weighted particle distribution weights by the sixth power of the size, the number of larger particles is smaller that is represented by the distribution reported by DLS in Fig. S3 . As the weight fraction of RIF in the core of RIF-VE formulations increases, the resuspension is better. Two populations are measured by DLS, where the smaller peak corresponds to the primary particle size and the larger peak has an average value that corresponds to a S f /S i = 3.4 and 54% of the intensity weighted distribution and S f /S i = 6 and 30% of the intensity weighted distribution for NC3 and NC4, respectively. While we present the particle size distribution computed from the correlation function for the light scattering of the suspensions without transformation of the data, the population of aggregates scatter more light than the smaller populations, and the intensity weighted particle size distributions scales the number of particles to the 6/5 power of the diameter [4] . Therefore, the number population of aggregates is smaller than estimated by dynamic light scattering.
S.4. Calibration curves
The concentration of SQ641 in standard dilutions was correlated to the integrated area under the curve from the HPLC chromatogram ( Fig. S4) Column with UV detection at 210 nm. Calibration curves for CsA and SQ641 were used to determined the concentration of the drugs in each preparation (Fig. S5 ).
S.5. SQ641 Nanocarrier suspension stability
The stability of the filtered nanocarrier suspension was tracked by DLS measurements over the 10 days following Flash NanoPrecipitation. After dialysis and filtration as described in the main text, the particles formed with a ratio of 0.5:1 and 1:1 are very stable, as shown by the constant size measured by DLS in Fig. S6 . There is more intra-and inter-day variability for the particles formed with 1.5:1 and 2:1 Figure S6 . Stability of SQ641 nanocarrier formulations, with VE to SQ641 ratios of 0.5:1 ( ), 1:1 ( ), 1.5:1 ( ), and 2:1 (). The nanocarrier suspension size is tracked by DLS measurements and the intensity average particle diameter is reported for two replicate measurements, each measurement was the average of 10-14 10 s segments of data collection. ratios of VE to SQ641. Both of these formulations undergo a slight increase in size over the 10 day period of observation. The cause for the large variability on the first day of measurements is due to shifting of the average value reported for multiple measurements, which does not occur on subsequent days. Each data point and error bar is the average and standard deviation, respectively, of two separate measurements, consisting of at least 10-14 measurements of 10 s each.
S.6.
In vitro testing conditions One of the primary benefits of formulating hydrophobic drugs into block copolymer stabilized nanocarriers is that high concentrations of drug in suspension can be achieved, facilitating the preclinical and clinical testing of drugs at relevant concentrations in aqueous media. In circulation, protected nanocarriers alter the pharmacokinetics of the free drug by extending circulation time and changing biodistribution. Ideally, nanocarrier formulations should be characterized in vitro, to determine if the necessary performance criteria, like drug release rates and efficacy, have been met. However, it is not straightforward to develop a discriminating in vitro assay for nanocarrier activity against an intracellular pathogen by using cell culture. Nanocarriers are developed to aid in drug delivery in circulation, in which there are flow conditions, the presence of a large volume of hydrophobic "sinks", and passage through various types of "filtration" organs, like the liver, spleen, and kidney. While "lab on a chip" assays are being developed that mimic in vivo conditions more closely, this next generation of materials are only at the prototype stage. As such, incubation of nanocarrier formulations in wells with cells serves as the first stage of comparison against the "soluble" 
